Teva Pharmaceutical Industries Limited (TEVA.TA)
TEVA.TA Stock Price Chart
Explore Teva Pharmaceutical Industries Limited interactive price chart. Choose custom timeframes to analyze TEVA.TA price movements and trends.
TEVA.TA Company Profile
Discover essential business fundamentals and corporate details for Teva Pharmaceutical Industries Limited (TEVA.TA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
12 Aug 2002
Employees
37.00K
Website
https://www.tevapharm.comCEO
Richard D. Francis
Description
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
TEVA.TA Financial Timeline
Browse a chronological timeline of Teva Pharmaceutical Industries Limited corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 May 2026
Upcoming earnings on 27 Jan 2026
Upcoming earnings on 4 Nov 2025
Earnings released on 30 Jul 2025
EPS came in at ILA 0.81 falling short of the estimated ILA 2.09 by -61.10%, while revenue for the quarter reached ILA 13.98B , beating expectations by +220.25%.
Earnings released on 6 May 2025
EPS came in at ILA 0.50 surpassing the estimated ILA 0.46 by +9.89%, while revenue for the quarter reached ILA 3.89B , missing expectations by -1.08%.
Earnings released on 29 Jan 2025
EPS came in at ILA 0.71 surpassing the estimated ILA 0.67 by +5.97%, while revenue for the quarter reached ILA 15.37B , beating expectations by +273.04%.
Earnings released on 6 Nov 2024
EPS came in at ILA 0.69 surpassing the estimated ILA 0.66 by +4.55%, while revenue for the quarter reached ILA 16.40B , beating expectations by +5.09%.
Earnings released on 31 Jul 2024
EPS came in at ILA 0.61 surpassing the estimated ILA 0.57 by +7.02%, while revenue for the quarter reached ILA 15.68B , beating expectations by +4.42%.
Earnings released on 8 May 2024
EPS came in at ILA 0.48 falling short of the estimated ILA 0.52 by -7.69%, while revenue for the quarter reached ILA 14.08B , missing expectations by -0.04%.
Earnings released on 31 Jan 2024
EPS came in at ILA 1.00 surpassing the estimated ILA 0.76 by +31.58%, while revenue for the quarter reached ILA 16.04B , beating expectations by +335.18%.
Earnings released on 8 Nov 2023
EPS came in at ILA 0.60 matching the estimated ILA 0.60, while revenue for the quarter reached ILA 14.75B , beating expectations by +297.54%.
Earnings released on 2 Aug 2023
EPS came in at ILA 0.56 surpassing the estimated ILA 0.53 by +5.66%, while revenue for the quarter reached ILA 14.27B , beating expectations by +325.37%.
Earnings released on 10 May 2023
EPS came in at ILA 0.40 falling short of the estimated ILA 0.56 by -28.57%, while revenue for the quarter reached ILA 13.11B , beating expectations by +259.76%.
Earnings released on 8 Feb 2023
EPS came in at ILA 0.71 falling short of the estimated ILA 0.76 by -6.58%, while revenue for the quarter reached ILA 13.39B , missing expectations by -1.25%.
Earnings released on 3 Nov 2022
EPS came in at ILA 0.59 falling short of the estimated ILA 0.63 by -6.35%, while revenue for the quarter reached ILA 12.72B , missing expectations by -4.41%.
Earnings released on 27 Jul 2022
EPS came in at ILA 0.68 surpassing the estimated ILA 0.60 by +13.33%, while revenue for the quarter reached ILA 13.18B , beating expectations by +2.21%.
Earnings released on 3 May 2022
EPS came in at ILA 0.55 falling short of the estimated ILA 0.61 by -9.84%, while revenue for the quarter reached ILA 11.69B , missing expectations by -3.23%.
Earnings released on 9 Feb 2022
EPS came in at ILA 0.77 surpassing the estimated ILA 0.72 by +6.94%, while revenue for the quarter reached ILA 12.73B , missing expectations by -6.50%.
Earnings released on 27 Oct 2021
EPS came in at ILA 0.59 falling short of the estimated ILA 0.64 by -7.81%, while revenue for the quarter reached ILA 12.50B .
Earnings released on 28 Jul 2021
EPS came in at ILA 0.59 falling short of the estimated ILA 0.63 by -6.35%, while revenue for the quarter reached ILA 12.75B .
Earnings released on 28 Apr 2021
EPS came in at ILA 0.63 surpassing the estimated ILA 0.61 by +3.28%, while revenue for the quarter reached ILA 13.26B .
Earnings released on 10 Feb 2021
EPS came in at ILA 0.68 surpassing the estimated ILA 0.63 by +7.94%, while revenue for the quarter reached ILA 14.30B .
Earnings released on 5 Nov 2020
EPS came in at ILA 0.58 falling short of the estimated ILA 0.59 by -1.69%, while revenue for the quarter reached ILA 13.63B .
TEVA.TA Stock Performance
Access detailed TEVA.TA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.